United Therapeutics (NASDAQ:UTHR) Price Target Raised to $575.00

United Therapeutics (NASDAQ:UTHR) had its target price raised by Wells Fargo & Company from $486.00 to $575.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock.

Several other research analysts have also weighed in on UTHR. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright increased their price target on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Price Performance

Shares of UTHR stock opened at $564.81 on Tuesday. The company has a market capitalization of $24.76 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75. The firm’s 50-day moving average is $504.78 and its two-hundred day moving average is $477.55. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.19 EPS. Sell-side analysts forecast that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $25,561,479.64. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $581.63, for a total value of $5,525,485.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $23,563,576.19. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 361,820 shares of company stock valued at $182,730,910 over the last quarter. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.